Hepatic tissue engineering.
Fulminant hepatic failure (FHF) attributes to rising medical cost and accounts for many deaths each year in the United States. Currently, the only solution is organ transplantation. Due to increasing donor organ shortage, many in need of transplantation continue to remain on the waiting list. Liver Assist Devices (LADs) are being used to temporarily sustain liver function and bridge the period between FHF and transplantation. Hepatic Tissue Engineering is a step toward alleviating the need for donor organs; yet many challenges must be overcome including scaffold choice, cell source and immunological barriers. Bioreactors have aided in hepatocyte survival and have proven to sustain viable cells for several weeks. Achieving the necessary functions required for hepatic replacement is aided by the incorporation of growth factors and mitogens many that now can be bound to the polymer scaffold and released in a timely manner. Utilizing concepts such as MicroElectroMechanical systems (MEMs) technology, our laboratory is able to mimic the natural vasculature of the liver and sustain functional and viable hepatocytes. Expanding and improving upon this platform technology, advancements made will continue toward the development of a fully functioning and implantable liver.
Kulig
Katherine M
KM
Massachusetts General Hospital, Warren 11, 55 Fruit Street, Boston, MA 02114, USA.
Vacanti
Joseph P
JP
D000818:Animals; D019149:Bioreactors; D018929:Cell Culture Techniques; D002470:Cell Survival; D022781:Hepatocytes; D006801:Humans; D017114:Liver Failure, Acute / Q000628:therapy*; D019164:Liver, Artificial; D014019:Tissue Donors / Q000600:supply & distribution; D023822:Tissue Engineering